skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Neovascular glaucoma after helium ion irradiation for uveal melanoma

Journal Article · · Ophthalmology (Rochester, Minn.); (United States)

Neovascular glaucoma developed in 22 of 169 uveal melanoma patients treated with helium ion irradiation. Most patients had large melanomas; no eyes containing small melanomas developed anterior segment neovascularization. The mean onset of glaucoma was 14.1 months (range, 7-31 months). The incidence of anterior segment neovascularization increased with radiation dosage; there was an approximately three-fold increase at 80 GyE versus 60 GyE of helium ion radiation (23% vs. 8.5%) (P less than 0.05). Neovascular glaucoma occurred more commonly in larger tumors; the incidence was not affected by tumor location, presence of subretinal fluid, nor rate of tumor regression. Fifty-three percent of patients had some response with intraocular pressures of 21 mmHg or less to a combination of antiglaucoma treatments.

Research Organization:
Univ. of California, San Francisco
OSTI ID:
5528569
Journal Information:
Ophthalmology (Rochester, Minn.); (United States), Vol. 2
Country of Publication:
United States
Language:
English

Similar Records

Risk Factors for Neovascular Glaucoma After Proton Beam Therapy of Uveal Melanoma: A Detailed Analysis of Tumor and Dose–Volume Parameters
Journal Article · Tue Oct 01 00:00:00 EDT 2013 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:5528569

Risk factors for neovascular glaucoma after carbon ion radiotherapy of choroidal melanoma using dose-volume histogram analysis
Journal Article · Thu Feb 01 00:00:00 EST 2007 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:5528569

Neovascular Glaucoma After Stereotactic Radiotherapy for Juxtapapillary Choroidal Melanoma: Histopathologic and Dosimetric Findings
Journal Article · Wed Jun 01 00:00:00 EDT 2011 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:5528569